United Kingdom · Question · Written question
UIN 101536
Tirzepatide
Introduced
18 December 2025
Last action
5 January 2026 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
5 January 2026
Summary
To ask the Secretary of State for Health and Social Care, what assessment they have made of variations in access to Tirzepatide (Mounjaro) across Integrated Care Boards; and what steps they are taking to ensure consistency in prescribing for eligible pati
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
18 December 2025
Written question
To ask the Secretary of State for Health and Social Care, what assessment they have made of variations in access to Tirzepatide (Mounjaro) across Integrated Care Boards; and what steps they are taking to ensure consistency in prescribing for eligible pati
Source: Commons
5 January 2026
Answer
Tirzepatide, brand name Mounjaro, is recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of both type 2 diabetes and obesity.Integrated care boards (ICBs) are legally required to fund NICE-recommended medicines, i...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-12-18/101536
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1866146
- uk · wq-1866146 · source updated 5 January 2026